Threads
All Filings
SEC Comment Letters
Company Responses
Letter Text
ENvue Medical, Inc.
Response Received
2 company response(s)
High - file number match
SEC wrote to company
2025-02-20
ENvue Medical, Inc.
Summary
Generating summary...
↓
↓
ENvue Medical, Inc.
Response Received
1 company response(s)
High - file number match
SEC wrote to company
2023-09-19
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2023-09-19
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Response Received
1 company response(s)
High - file number match
SEC wrote to company
2023-08-09
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2023-08-09
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Response Received
1 company response(s)
High - file number match
SEC wrote to company
2020-12-14
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2020-12-14
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Response Received
1 company response(s)
High - file number match
SEC wrote to company
2020-07-28
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2020-08-10
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Response Received
1 company response(s)
High - file number match
Company responded
2020-01-27
ENvue Medical, Inc.
Summary
Generating summary...
↓
SEC wrote to company
2020-01-28
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Response Received
2 company response(s)
High - file number match
SEC wrote to company
2019-02-05
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2019-02-14
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2019-05-21
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Response Received
1 company response(s)
High - file number match
SEC wrote to company
2017-06-23
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2017-11-01
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Response Received
1 company response(s)
Medium - date proximity
SEC wrote to company
2017-09-18
ENvue Medical, Inc.
Summary
Generating summary...
↓
Company responded
2017-10-31
ENvue Medical, Inc.
Summary
Generating summary...
ENvue Medical, Inc.
Awaiting Response
0 company response(s)
High
SEC wrote to company
2017-07-13
ENvue Medical, Inc.
Summary
Generating summary...
Summary
| Date | Type | Company | Location | File No | Link |
|---|---|---|---|---|---|
| 2025-05-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2025-05-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2025-02-20 | SEC Comment Letter | ENvue Medical, Inc. | DE | 333-284973 | Read Filing View |
| 2023-09-19 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2023-09-19 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2023-08-09 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2023-08-09 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-12-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-12-14 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-08-10 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-07-28 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-01-28 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-01-27 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2019-05-21 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2019-02-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2019-02-05 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-11-01 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-10-31 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-09-18 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-07-13 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-06-23 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| Date | Type | Company | Location | File No | Link |
|---|---|---|---|---|---|
| 2025-02-20 | SEC Comment Letter | ENvue Medical, Inc. | DE | 333-284973 | Read Filing View |
| 2023-09-19 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2023-08-09 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-12-14 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-07-28 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-01-28 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2019-02-05 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-09-18 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-07-13 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-06-23 | SEC Comment Letter | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| Date | Type | Company | Location | File No | Link |
|---|---|---|---|---|---|
| 2025-05-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2025-05-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2023-09-19 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2023-08-09 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-12-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-08-10 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2020-01-27 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2019-05-21 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2019-02-14 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-11-01 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
| 2017-10-31 | Company Response | ENvue Medical, Inc. | DE | N/A | Read Filing View |
2025-05-14 - CORRESP - ENvue Medical, Inc.
CORRESP 1 filename1.htm Dawson James Securities, Inc. 101 North Federal Highway, Suite 600 Boca Raton, Fl 33432 May 14, 2025 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NanoVibronix, Inc. Registration Statement on Form S-1/A File No. 333-284973 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), we, the placement agent, hereby request that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced registration statement on Form S-1/A (the "Registration Statement") to become effective at 4:00 p.m., Eastern Time, on Wednesday, May 14, 2025 or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated May 14, 2025 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. If you require any additional information with respect to this letter, please contact Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP. Very truly yours, DAWSON JAMES SECURITIES, INC. By: /s/ Robert D. Keyser, Jr. Robert D. Keyser, Jr. Chief Executive Officer cc: M. Ali Panjwani, Esq. Pryor Cashman LLP
2025-05-14 - CORRESP - ENvue Medical, Inc.
CORRESP 1 filename1.htm NanoVibronix, Inc. 969 Pruitt Place Tyler TX 75703 May 14, 2025 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Jane Park Re: NanoVibronix, Inc. Registration Statement on Form S-1 Originally filed on February 14, 2025, as amended on April 22, 2025, April 29, 2025, May 12, 2025, and May 14, 2025 File No. 333-284973 (as amended, the "Registration Statement") Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the " Commission ") under the Securities Act of 1933, as amended, NanoVibronix, Inc. (the " Company "), hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:00 p.m., Eastern Time, on May 14, 2025, or as soon thereafter as practicable. Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Alla Digilova, Esq. at (212) 659-4993. Very truly yours, Nanovibronix, Inc. By: /s/ Stephen Brown Stephen Brown Chief Financial Officer cc: Alla Digilova, Esq., Haynes and Boone, LLP
2025-02-20 - UPLOAD - ENvue Medical, Inc. File: 333-284973
February 20, 2025
Brian Murphy
Chief Executive Officer
NanoVibronix, Inc.
969 Pruitt Place
Tyler, TX 75703
Re:NanoVibronix, Inc.
Registration Statement on Form S-1
Filed February 14, 2025
File No. 333-284973
Dear Brian Murphy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Alla Digilova, Esq.
2023-09-19 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix,
Inc.
525
Executive Boulevard
Elmsford,
New York 10523
September
19, 2023
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Industrial Applications and Services
Securities
and Exchange Commission
Washington,
D.C. 20549
Attention:
Nicholas O’Leary
Re:
NanoVibronix,
Inc.
Registration
Statement on Form S-3
Filed
on September 12, 2023
File No. 333-274482 (the “Registration Statement”)
Request
for Acceleration
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under
the Securities Act of 1933, as amended, NanoVibronix, Inc. (the “Company”) hereby respectfully requests acceleration
of the effective date of the Registration Statement, so that it may become effective at 10:00 a.m., Eastern Time, on September
21, 2023, or as soon thereafter as practicable.
Should
any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes
and Boone, LLP, attention: Jayun Koo, Esq. at (212) 835-4823.
Very truly yours,
NANOVIBRONIX, INC.
By:
/s/ Brian
Murphy
Brian Murphy
Chief Executive Officer
cc:
Jayun Koo, Esq., Haynes and Boone, LLP
2023-09-19 - UPLOAD - ENvue Medical, Inc.
United States securities and exchange commission logo
September 19, 2023
Brian Murphy
Chief Executive Officer
NanoVibronix, Inc.
525 Executive Blvd
Elmsford, New York 10523
Re:NanoVibronix, Inc.
Registration Statement on Form S-3
Filed September 12, 2023
File No. 333-274482
Dear Brian Murphy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Nicholas O'Leary at 202-551-4451 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Jayun Koo, Esq.
2023-08-09 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix,
Inc.
525
Executive Boulevard
Elmsford,
New York 10523
August
9, 2023
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Industrial Applications and Services
Securities
and Exchange Commission
Washington,
D.C. 20549
Attention:
Abby Adams
Re:
NanoVibronix,
Inc.
Registration
Statement on Form S-3
Filed
on August 1, 2023
File
No. 333-273574 (the “Registration Statement”)
Request
for Acceleration
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under
the Securities Act of 1933, as amended, NanoVibronix, Inc. (the “Company”) hereby respectfully requests acceleration
of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on August 11, 2023,
or as soon thereafter as practicable.
Should
any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes
and Boone, LLP, attention: Jayun Koo, Esq. at (212) 835-4823.
Very
truly yours,
NANOVIBRONIX,
INC.
By:
/s/
Brian Murphy
Brian
Murphy
Chief
Executive Officer
cc:
Jayun
Koo, Esq., Haynes and Boone, LLP
2023-08-09 - UPLOAD - ENvue Medical, Inc.
United States securities and exchange commission logo
August 8, 2023
Stephen Brown
Chief Financial Officer
NanoVibronix, Inc.
525 Executive Boulevard
Elmsford, NY 10523
Re:NanoVibronix, Inc.
Registration Statement on Form S-3
Filed August 1, 2023
File No. 333-273574
Dear Stephen Brown:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Jayun Koo, Esq.
2020-12-14 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix,
Inc.
525
Executive Boulevard
Elmsford,
New York 10523
December
14, 2020
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Securities
and Exchange Commission
Washington,
D.C. 20549
Attention:
Jason L. Drory
Re:
NanoVibronix,
Inc.
Registration
Statement on Form S-3
Filed
on December 10, 2020
File
No. 333-251264 (the “Registration Statement”)
Request
for Acceleration
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended, NanoVibronix, Inc. (the “Company”) hereby respectfully
requests acceleration of the effective date of the Registration Statement so that it may become effective at 5:00 p.m., Eastern
Time, on December 15, 2020, or as soon thereafter as practicable.
Should
any member of the staff of the Commission have
any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A.
Werner, Esq. at (212) 659-4974.
Very
truly yours,
NANOVIBRONIX,
INC.
By:
/s/
Brian Murphy
Brian
Murphy
Chief
Executive Officer
cc:
Rick
A. Werner, Esq., Haynes and Boone, LLP
2020-12-14 - UPLOAD - ENvue Medical, Inc.
United States securities and exchange commission logo
December 14, 2020
Brian Murphy
Chief Executive Officer
NanoVibronix, Inc.
525 Executive Blvd.
Elmsford, NY 10523
Re:NanoVibronix, Inc.
Registration Statement on Form S-3
Filed December 10, 2020
File No. 333-251264
Dear Mr. Murphy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason L. Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rick Werner, Esq.
2020-08-10 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix,
Inc.
525
Executive Boulevard
Elmsford,
New York 10523
August
10, 2020
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Securities
and Exchange Commission
Washington,
D.C. 20549
Attention:
Courtney Lindsay
Re:
NanoVibronix,
Inc.
Registration
Statement on Form S-3
Filed
on July 21, 2020
File
No. 333-239965 (the “Registration Statement”)
Request
for Acceleration
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended, NanoVibronix, Inc. (the “Company”) hereby respectfully
requests acceleration of the effective date of the Registration Statement so that it may become effective at 5:00 p.m., Eastern
Time, on August 11, 2020, or as soon thereafter as practicable.
Should
any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel,
Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very
truly yours,
NANOVIBRONIX,
INC.
By:
/s/
Brian Murphy
Brian
Murphy
Chief
Executive Officer
cc:
Rick A. Werner, Esq., Haynes and Boone, LLP
2020-07-28 - UPLOAD - ENvue Medical, Inc.
United States securities and exchange commission logo
July 28, 2020
Brian Murphy
Chief Executive Officer
NanoVibronix, Inc.
525 Executive Boulevard
Elmsford, New York 10523
Re:NanoVibronix, Inc.
Registration Statement on Form S-3
Filed July 21, 2020
File No. 333-239965
Dear Mr. Murphy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Courtney Lindsay at (202) 551-7237 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
2020-01-28 - UPLOAD - ENvue Medical, Inc.
January 27, 2020
Brian Murphy
Chief Executive Officer
NanoVibronix, Inc.
525 Executive Blvd.
Elmsford, New York
Re:NanoVibronix, Inc.
Registration Statement on Form S-3
Filed January 22, 2020
File No. 333-236000
Dear Mr. Murphy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jayun Koo, Esq.
2020-01-27 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix, Inc.
525 Executive Blvd.
Elmsford, NY 10523
January 27, 2020
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: Chris Edwards
RE:
NanoVibronix, Inc.
Registration Statement on Form S-3
Filed January 22, 2020 (the “Registration Statement”)
Request for Acceleration
File No. 333-236000
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated
under the Securities Act of 1933, as amended, NanoVibronix, Inc. (the “Company”) hereby respectfully requests
acceleration of the effective date of the Registration Statement so that it may become effective at 5:00 p.m., Eastern Time, on
January 29, 2020, or as soon thereafter as practicable.
Should any member of the
staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact
our counsel, Haynes and Boone, LLP, attention: Jayun Koo, Esq. at (212) 835-4823.
Very truly yours,
NanoVibronix, Inc.
By:
/s/ Brian Murphy
Brian Murphy
Chief Executive Officer
cc: Rick A. Werner, Esq., Haynes and Boone, LLP
2019-05-21 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix,
Inc.
525 Executive Blvd.
Elmsford, New York 10523
(914) 233-3004
May 21, 2019
Via
EDGAR Correspondence
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.W.
Washington,
D.C. 20549
Re:
NanoVibronix, Inc.
Registration
Statement on Form S-3
Initially
Filed December 31, 2018
File
No. 333-229106
Ladies
and Gentlemen:
NanoVibronix,
Inc. (the “Company”) is enclosing herewith an acceleration request with respect to the above captioned registration
statement. In connection with such request, the Company hereby acknowledges that:
● should
the Commission or the staff, acting pursuant to delegated authority, declare the registration
statement effective, it does not foreclose the Commission from taking any action with
respect to the registration statement;
● the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the registration statement effective, does not relieve the Company from its full responsibility
for the adequacy and accuracy of the disclosure in the registration statement; and
● the
Company may not assert staff comments and the declaration of effectiveness as a defense
in any proceeding initiated by the Commission or any person under the federal securities
laws of the United States.
Very truly yours,
NanoVibronix, Inc.
By:
/s/ Stephen Brown
Name: Stephen Brown
Title: Chief Financial Officer
cc: Brian
Murphy, Chief Executive Officer, NanoVibronix, Inc.
Aurora
Cassirer, Esq. Troutman Sanders, LLP
Joseph
Walsh, Esq., Troutman Sanders, LLP
NanoVibronix,
Inc.
525 Executive Blvd.
Elmsford, New York 10523
(914) 233-3004
May 21, 2019
Via
EDGAR Correspondence
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.W.
Washington,
D.C. 20549
Re:
NanoVibronix, Inc.
Registration
Statement on Form S-3
Initially
Filed December 31, 2018
File
No. 333-229106
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Securities Act of 1933, as amended, the undersigned registrant under the above-referenced registration statement
hereby requests acceleration of the effective date of the registration statement to May 23, 2019, at 4:00 p.m., New York time,
or as soon as practicable thereafter. Please notify our outside counsel, Joseph Walsh, Esq., by phone at (212) 704-6030, by fax
at (212) 704-5919, or by email at joseph.walsh@troutman.com of the date and time that the registration statement has been
declared effective.
Very truly yours,
NanoVibronix, Inc.
By:
/s/ Stephen Brown
Name: Stephen Brown
Title: Chief Financial Officer
cc: Brian
Murphy, Chief Executive Officer, NanoVibronix, Inc.
Aurora
Cassirer, Esq. Troutman Sanders, LLP
Joseph
Walsh, Esq., Troutman Sanders, LLP
2019-02-14 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix, Inc.
525 Executive Blvd.
Elmsford, NY 10523
February 14, 2019
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: Eric Atallah
RE:
NanoVibronix, Inc.
Registration Statement on Form S-3
Filed December 31, 2018
Request for Acceleration
File No. 333-229106
Ladies and Gentlemen:
Pursuant to Rule 461 of
the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities
Act of 1933, as amended, NanoVibronix, Inc. (the “Company”) hereby requests acceleration of the effective date
of the above-mentioned Registration Statement on Form S-3 (the “Registration Statement”) to 5:00 p.m., Eastern
Time on February 15, 2019, or as soon thereafter as practicable.
Should any member of the
staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact
our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
NanoVibronix, Inc.
By:
/s/ Stephen Brown
Stephen Brown
Chief Financial Officer
2019-02-05 - UPLOAD - ENvue Medical, Inc.
February 5, 2019
Stephen Brown
Chief Financial Officer
NanoVibronix, Inc.
525 Executive Blvd.
Elmsford, New York
Re:NanoVibronix, Inc.
Registration Statement on Form S-3
Filed December 31, 2018
File No. 333-229106
Dear Mr. Brown:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Eric Atallah at (202) 551-3663 with any questions.
Sincerely,
Division of Corporation Finance
Office of Electronics and Machinery
cc: Rick Werner
2017-11-01 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
November
1, 2017
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
NanoVibronix, Inc.
Registration Statement on Form S-1
File No. 333-218871
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as underwriter of the proposed offering, hereby joins
the request of NanoVibronix, Inc. that the effective date of the above-referenced Registration Statement on Form S-1 be declared
effective at 5:00 p.m. (Washington, D.C. time) on Wednesday, November 1, 2017, or as soon as practicable thereafter.
In
connection with the proposed offering of the Company’s securities, copies of the preliminary prospectuses dated October
31, 2017 were distributed to the following persons in the following approximate amounts:
To Whom Distributed
Number of Copies
Institutions
50
Individuals
1,892
Total
1,942
We
have complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Sincerely,
Dawson James Securities, Inc.
By:
/s/ Thomas W. Hands
Name:
Thomas W. Hands
Title:
President
2017-10-31 - CORRESP - ENvue Medical, Inc.
CORRESP
1
filename1.htm
NanoVibronix,
Inc.
9
Derech Hashalom Street
Nesher,
Israel 36651
October
31, 2017
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Securities and Exchange Commission
Washington, D.C. 20549
Attention:
Timothy Buchmiller
Re:
NanoVibronix, Inc.
Registration Statement on Form S-1, originally filed on June 21, 2017
File
No. 333- 218871, as amended (the “Registration Statement”)
Request
for Acceleration
Ladies
and Gentlemen:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, NanoVibronix, Inc. (the “Company”)
hereby respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective
at 5:00 p.m., Eastern Time, on November 1, 2017, or as soon thereafter as practicable.
Very truly yours,
NANOVIBRONIX, INC.
By:
/s/ Stephen Brown
Stephen Brown
Chief Financial Officer
cc: Rick
A. Werner, Esq., Haynes and Boone, LLP
2017-09-18 - UPLOAD - ENvue Medical, Inc.
Mail Stop 3030
September 18 , 2017
Via E -mail
Stephen Brown
Chief Financial Officer
NanoVibronix, Inc.
9 Derech Hashalom Street
Nesher, Israel 36651
Re: NanoVibronix, Inc.
Form 10 -K for the Fiscal Year Ended December 31, 2016
Filed March 31, 2017
File No. 001-36445
Dear Mr. Brown :
We have completed our review of your filing s. We remind you that the company and its
management are responsible for the accuracy and adequacy of the ir disclosure s, notwithstanding
any review, comments, action or absence of action by the staff .
Sincerely,
/s/ Martin James
Martin James
Senior Assistant Chief Accountant
Office of Electronics and Machinery
2017-07-13 - UPLOAD - ENvue Medical, Inc.
Mail Stop 3030
July 13, 2017
Via E -mail
Stephen Brown
Chief Financial Officer
NanoVibronix, Inc.
9 Derech Hashalom Street
Nesher, Israel 36651
Re: NanoVibronix , Inc.
Form 10 -K for the Fiscal Year Ended December 31 , 2016
Filed March 31, 2017
Form 10 -Q for the Quarterly Period Ended March 31, 2017
Filed May 15 , 2017
File No. 001-36445
Dear Mr. Brown :
We have limited our review of your filing to the financial statements and related
disclosures and have the following comments. In some of our comments, we may ask you to
provide us with information so we may better understand your disclosure.
Please respond to these comments within ten business days b y providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response to these comments , we may have additional comments.
Form 10 -K for the Year Ended December 31, 2016
Consolidated Financial Statements
Consolidated Statements of Comprehensive Loss, page F -5
1. Revise this statement and other applicable sections of future filin gs to use parentheses to
clearly show Operating loss, Loss before taxes on income, Net loss, and Total
comprehensive loss as negative amounts, similar to your presentation s of the net loss per
share amounts here and net loss in the statements of cash flows.
Stephen Brown
NanoVibronix, Inc.
July 13 , 2017
Page 2
Exhibits 31.1 and 31.2 Certifications Pursuant to Rule 13 -a-14(a)
2. On page 48, you correctly include Management’s Report on Internal Control over
Financial Reporting as of December 31, 2016. Please amend the filing to provide
currently dated certifications that ar e consistent with the language in Item 601(b)(31) of
Regulation S -K, including the required language pertaining to your the internal control
over financial reporting in the introduction to paragraph 4 and paragraph 4(b) in its
entirety. This comment also a pplies to your Form 10 -Q for the period ended March 31,
2017.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the st aff.
You may contact Dennis Hult at (202) 551 -3618, or me at (202) 551 -3671with any
questions.
Sincerely,
/s/ Martin James
Martin J ames
Senior Assistant Chief Accountant
Office of Electronics and Machinery
2017-06-23 - UPLOAD - ENvue Medical, Inc.
Mail Stop 3030 June 23, 2017 Brian Murphy Chief Executive Officer NanoVibronix, Inc. 9 Derech Hashalom Street Nesher, Israel 36651 Re: NanoVibronix, Inc. Registration Statement on Form S-1 Filed June 21, 2017 File No. 333-218871 Dear Mr. Murphy : Our preliminary review of your registration statement indicates that it fails in numerous material respects to comply with the requirements of the Securities Ac t of 1933, the rules and regulations under that Act, and the requirements of the form. The financial statements do not comply with Rule 8 -08 of Regulation S -X. We will not perform a detailed examination of the registration statement and we will not issue comments. If you were to request acceleration of the effective date of the registration statement in its present form, we would likely recommend that the Commission deny your request. You may contact Tim Buchmiller at (202) 551 -3635 with any questions. Sincerely, /s/ Amanda Ravitz Amanda Ravitz Assistant Director Office of Electronics and Machinery cc: Rick A. Werner, Esq. Haynes and Boone, LLP